Century Therapeutics, Inc.
IPSC
$0.62
$0.023.28%
NASDAQ
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | 2,515.96% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | 2,515.96% | |||
| Cost of Revenue | 1.05% | -9.51% | |||
| Gross Profit | -132.52% | 427.69% | |||
| SG&A Expenses | -7.17% | -7.72% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -0.93% | -9.09% | |||
| Operating Income | -146.73% | 316.17% | |||
| Income Before Tax | -142.50% | 323.23% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -142.50% | 312.24% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -142.50% | 312.24% | |||
| EBIT | -146.73% | 316.17% | |||
| EBITDA | -140.65% | 349.71% | |||
| EPS Basic | -142.39% | 310.75% | |||
| Normalized Basic EPS | -142.39% | 342.71% | |||
| EPS Diluted | -142.70% | 310.75% | |||
| Normalized Diluted EPS | -142.43% | 342.50% | |||
| Average Basic Shares Outstanding | 0.25% | 0.71% | |||
| Average Diluted Shares Outstanding | 0.16% | 0.80% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||